Investigating the various T2D treatment regimens, including insulin, metformin, sodium-glucose transport protein 2 (SGLT2) inhibitors, DPP4 inhibitors, sulfonylureas, and GLP-1 receptor agonists, can be performed by examining their influence on immune pathways that mediate the viral replication or host response. This evidence concerns the gene INS and type 2 diabetes mellitus.